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It has been widely appreciated for more than a century that
thromboses in the arterial and venous beds and in the heart
are major causesand importantcomplicationsof manyforms
of cardiovascular disease. Whereas early observers consid-
ered thrombosis to be the primary cause of transmural myo-
cardial infarction, later investigators seriously questioned
this concept because of the frequent absence of thrombosis
in the infarct-related artery at postmortem examination.
Streptokinase and urokinase, the so-called first generation
thrombolytic agents, became available for clinical use in
the 1960s and, although employed in a number of clinical
trials initially, were not widely used in the treatment of
acute myocardial infarction.
The situation changed radically and rapidly at the begin-
ning of this decade when coronary arteriography, carried
out during the first few hours of myocardial infarction, re-
vealed that coronary thrombosis indeed is the proximate
cause of transmural myocardial infarction in a large majority
of patients. This ohservation sparked enormous interest in
the thrombolytic therapy of acute myocardial infarction. At
first this involved the infusion of streptokinase directly into
[he occluded coronary vessel. Soon thereafter the tield ex-
panded in two important directions: I) Streptokinase (and
then other thrombolytic agents) were administered by the
intravenous rather than the intracoronary route to make
thrombolytic therapy available to patients in settings in which
a fully staffed cardiac catheterization laboratory is not avail-
able and to shorten the time interval between the onset of
symptoms and successful reperfusion; and 2) the develop-
ment of so-called second generation thrombolytic agents
that are more tibrin specific and effective than streptokinase
and urokinase.
Few times in the history of cardiology has a new ther-
apeutic development generated more excitement and interest
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and few times has clinical research to assess its efficacy
moved more swiftly. In contrast to some earlier therapeutic
advances, many investigationsof thrombolytic therapy have
been carefully designed prospectively, with clearly defined
end points and appropriate attention to sample size and to
other statistical considerations.
In an effort to keep cardiologists and internists current
in this rapidly advancing field, the Department of Contin-
uing Education of the Harvard Medical School conducted
a postgraduate course on Modern Thrombolytic Therapy in
association with the Annual Meeting of the American Col-
lege of Cardiology in March 1987. The presentations at this
course have been updated and are now available to the
readers of the Journal of the American College of Car-
diology in this supplement.
Thefirst four articles deal with a description of the var-
ious thrombolytic agents. Verstraete provides a helpful his-
torical perspective and summarizes the pharmacology of a
large number of these drugs, commencing with streptoki-
nase and urokinase and ending with thrombolytic agents still
under development. Collen then summarizes the known and
postulated molecular mechanisms of action of the relatively
new fibrin-specific thrombolytic agents, particularly the sec-
ond generation drugs, that is, recombinant tissue-type plas-
minogen activator (rt-PA) and single chain urokinase plas-
minogen activator (scu-PA or pro-urokinase). He describes
an interesting synergism between these two agents, and
discusses the development of mutants of rt-PA and seu-PA,
drugs that might be termed third generation thrombolytic
agents, some of which may possess greater tibrin affinities
and have a longer half-life than the second generation drugs,
Even more exciting is the early work on molecules that are
hybrids of rt-PA and seu-PA; perhaps these will become the
[ourth generation thrombolytic agents, From Verstraete's
and Collen's papers it is evident that we are still in the early
stages of development of thrombolytic agents and can an-
ticipate even more effective and more specific agents with
more favorable pharmacokinetic properties.
0735-I097/~7/$3.50
28 BRAL'NW'ALD
INTRODUCTION
lAce voi. In. No, 5
November 1'J~7 : IlJ- 31l
Gurewich presents early clinical experience with pro-
urokinase, and discusses further the synergism between this
drug and both rt-PA and urokinase. Another new throm-
bolytic agent. anisoylated plasminogen streptokinase acti-
vator complex (APSAC). has been designed to improve the
kinetic properties of the streptokinase-plasminogen com-
plex; it is inactive on injection. but is activated by hydrolysis
in a controlled fashion. Anderson reviews the pharmacology
of this interesting drug and the clinical experiences with its
use. APSAC can be administered as a bolus and is at least
as effective as the parent compound, streptokinase; it is not
yet dear whether or not it is more fibrin specific.
There has now been considerable clinical experience with
the lise ofboth intracoronary and intravenous streptokinase
ill the treatment of acute myocardial infarction. Kennedy
reviews the results of clinical trials with this agent (seven
trials with intracoronary and three with intravenous admin-
istration), an overview that indicates that this therapy im-
proves survival in some groups of patients with acute myo-
cardial infarction. The GISSI trial of intravenous strepto-
kinase. carried out on almost 12.000 patients in Italy
and reported in 1986, was a watershed study because it
showed quite clearly that improvement in survival during
the hospital phase of acute myocardial infarction can indeed
be obtained with intravenous streptokinase. particularly if
it is administered during the first 3 hours after the onset of
myocardial infarction. In the initial report it was not clear
whether this early improvement in survival would be sus-
tained after hospital discharge. Tognoni and Franzosi report
in this supplement that this improvement in survival is in-
deed sustained, at least for I year. This follow-up of patients
entered into the GISSI trial is especially meaningful because
of the very low rates of mechanical revascularization-
percutaneous transluminal coronary angioplasty and coro-
nary artery bypass grafting-that were utilized in Italy dur-
ing the course of the trial and that might have obscured the
results of thrombolytic therapy itself.
Sub stantial clinical experience has fW\l' been obta ined
with the use of intravenously injected tissue plasminogen
activator produced by recombinant techniques (rt-PA) in
the early treatment of myocardial infarction. In two ran-
domized, double-blind controlled trials it has been found to
be superior to intravenous streptokinase in reestablishing
coronary patency. Further experiences with rt-PA are re-
viewed in the next fi ve articles. The first three of these come
from the National Heart. Lung, and Blood Institute's
Thrombolysis in Myocardial Infarction (TIM!) trial. First,
Sobel reviews the overall experience with rt-PA in the TIMI
trial. focusing on both efficacy and adverse effects. Al-
though this drug appears to open occluded coronary arteries
more frequently while causing less biochemical perturbation
of the coagulation system than does streptokinase, in large
doses rt-PA can cause intracranial bleeding. Fortunately,
moderate doses appear to be quite effecti ve in establishing
coronary patency and rarely cause intracranial hemorrhage.
After successful thrombolysis many patients with evolving
myocardia! infarction are left with critically narrowed cora-
naryarteries. These vessels may reocc1ude promptly and,
even if they remain patent, these markedly narrowed vessels
could be responsible for demand-induced ischemia. Coro-
nary angioplasty is potentially useful in sustaining the ben-
efits of reperfusion in such patients. Williams et al. describe
the initial experience of the TIMI investigators with this
technique. In a sizable fraction of patients who had received
intravenous rt-PA 18 to 48 hours earlier. coronary angio-
plasty either was found to be unnecessary because of less
than critical obstruction of the infarct-related artery, or was
not feasible, because of complex coronary anatomy. How-
ever, despite the somewhat limited applicability of angio-
plasty in this setting, thrombolysis followed by angioplasty
was successful in almost all patients in whom it was indi-
cated and attempted.
Passamani et al . then describe the TiMllf trial, an on-
going study designed to determine whether coronary angio-
plasty (if the latter is found to be feasible and indicated)
should be carried out routinely after thrombolytic therapy
or, alternatively, if the more conservative strategy of
" watchful waiting" should be pursued, subjecting the pa-
tient to coronary arteriography followed by mechanical rc-
vascularization only if recurrent ischemia becomes manifest.
Before this large, complex trial was initiated. an open pilot
study was carried out to test the protocol. Analysis of the
pilot study revealed that a moderately aggressive approach
to repcrfusion therapy. that is. intravenous administration
of rt-PA within 4 hours of acute myocardial infarction fol-
lowed 18 to 48 hours later by coronary arteriography and,
when feasible and indicated, by coronary angioplasty, can
result in the remarkably low early mortality rate of 4% and
patent infarct-related coronary arteries without critical ob-
struction in approximately two-thirds of patients. The results
of the ongoing trial are necessary to determine how this
moderately aggressive strategy compares with a less ag-
gressive regimen, rt-PA followed by watchful waiting, or
by a more aggressive approach. rt-PA followed by imme-
diate coronary angiography and coronary angioplasty. What
appears to be clear at this point is that the intermediate
course provides excellent results in terms of survival and
patency of the infarct-related coronary artery.
Topol and Califf then report on the results of the Throm-
bolysis and An gioplasty in Myocardial Infarction (TAMI)
trial. which suggest that the very aggressive approach to the
treatment of acute myocardial infarction , emergency coro-
nary arteriography during rt-PA infusion followed by me-
chanical revascularization, may be most appropriate for high
risk patients. whereas patients at lower risk may be best
managed by intravenous rt-PA with later treatment deter-
mined by predischarge exercise testing or coronary arteri-
ography. or both.
The role of rt-PA in the management of acute myocardial
infarction is being studied with equal vigor on both sides
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of the Atlantic . de Bono summarizes the results of the Eu-
ropean clinical trials with this agent. The comparisons be-
tween intravenous rt-PA and streptokinase were similar in
the European and the American (TIMl) trials. de Bono also
whets our appetite by describing the design of the ongoing
trials with rt-PA in acute myocardial infarction in Europe;
their results are awaited with great interest.
Altering the strategy of treatment of acute myocardial
infarction by means of early reperfusion will surclv affec:
the> COS(s of care of this condition and. given the high in-
cidenceof myocardial infarction, theeconomicconsequence
of such alterations may be quite substantial. Laffer et al.
consider this important problem and demonstrate that the
incremental costs and benefits of thrombolytic therapy de-
pend principally on the quantity of myocardium undergoing
infarction, the time after the onset of the event at which
reperfusion occurs and the degree of aggressiveness of
postthrombolytic therapy. Estimates of the costs of a life
saved by thrombolytic therapy in patients experiencing a
large infarction early in their course are within the range of
commonly accepted procedures but. as might be anticipated.
these costs are much higher in patients with a small infarc-
tion (in whom survival is excellent regardless of therapy),
patients who receive thrombolytic therapy relatively latc in
their course (in whom little myocardium can be salvaged)
and patients who are subjected to aggressive postthrorn-
holytic mechanical reperfusion therapy. The routine use of
postthrombolyticcoronary arteriography and mechanical rc-
perfusion, that is. coronary angioplasty and. if necessary.
coronary artery bypass grafting. adds greatly to the cost of
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thrombolytic therapy. Therefore, the results of the ongoing
TiMl and European trials designed to assess the efficacy
and to define the role of mechanical reperfusion therapy
after thrombolysis are significant not only from a medical
but also from an economic viewpoint.
The two last articles deal with thrombolytic therapy or
conditions mila OW/l acute myocardial infarction. Gold et
al. describe the use of the prolonged infusion of rt-PA in
patients with unstable angina who, like patients with acute
infarction. often have coronary thrombi. Although this reg-
imen appears to be effective in lysing such thrombi. it may
also cause excessive bleeding. When the details of dosage
and duration of administration have been optimized it is
likely that intravenous thrombolytic therapy will playa sig-
nificant role in the management of unstable angina. Finally,
Goldhaber ct al. present the favorable results of rt-PA in-
fusion in the lysis of pulmonary emboli. However. the clin-
iCC11 value of thrombolysis in the management of this con-
dition remains to he defined.
I believe that these 15 articles. when considered collec-
tively, demonstrate clearly that we have entered a new era
in the treatment of acute myocardial infarction and perhaps
of related conditions such as unstableangina and pulmonary
embolism. Mytask in editing this supplement was facilitated
by the contributors who provided excellent manuscripts in
a timel y manner. The Genentech Corporation provided an
educational grant to support publication of the supplement
as well as total freedom in selecting both the subjects and
contributors. Patricia Delosh and Carolyn Farley in my
office provided expert editorial and secretarial support.
